Serum prolactin and brain and pituitary monoamine responses to chronic monoamine oxidase inhibition in the rat.
The acute administration of the monoamine oxidase inhibitor iproniazid to rats causes a highly significant suppression of serum prolactin levels at 2 h. At the same time there is a significant rise in the hypothalamic-median eminence concentrations of the biogenic monoamines dopamine, noradrenaline and serotonin. When iproniazid is administered daily to rats for 4 days and the animals are examined on the fifth day brain noradrenaline and serotonin levels are elevated similarly to those seen after acute administration but dopamine concentration is near normal while serum prolactin is significantly elevated. This study thus demonstrates that a quite specific and unexpected change occurs in the regulation of hypothalamic-median eminence dopamine when iproniazid is administered chronically and provides an explanation of previous observations in human subjects where raised serum prolactin levels are observed after chronic therapy with monoamine oxidase inhibitors.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000818:Animals; D001679:Biogenic Amines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000032:analysis; D007031:Hypothalamus / Q000187:drug effects; D007490:Iproniazid / Q000494:pharmacology; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008473:Median Eminence / Q000187:drug effects / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009638:Norepinephrine / Q000032:analysis; D011388:Prolactin / Q000097:blood*; D051381:Rats; D012701:Serotonin / Q000032:analysis
D001679:Biogenic Amines; D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D007980:Levodopa; D011388:Prolactin; D006916:5-Hydroxytryptophan; D007490:Iproniazid; D004298:Dopamine; D009638:Norepinephrine